Achieve Life Sciences, Inc. carries a market capitalization of 505.08M, placing it among publicly traded companies globally. Its enterprise value stands at 127.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 505.08M |
| Enterprise Value | 127.07M |
Achieve Life Sciences, Inc. currently has 53.24M shares outstanding.
| Shares Outstanding | 53.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.52 |
| P/TBV Ratio | 15.80 |
| P/FCF Ratio | -3.12 |
| P/OCF Ratio | -3.12 |
Achieve Life Sciences, Inc. maintains a current ratio of 2.62, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 140.03, indicating elevated leverage, while an interest coverage ratio of -57.52 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.62 |
| Quick Ratio | 2.47 |
| Debt / Equity | 140.03 |
| Debt / EBITDA | -0.29 |
| Interest Coverage | -57.52 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -171.97 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Achieve Life Sciences, Inc.'s stock has gained approximately 16.86461% over the past 52 weeks. The 50-day moving average sits at 4.24, while the 200-day moving average is 4.18.
| Beta (5Y) | N/A |
| 52-Week Price Change | 16.86461% |
| 50-Day Moving Average | 4.24 |
| 200-Day Moving Average | 4.18 |
| Average Volume (20 Days) | N/A |
EBITDA reached -52.23M, while operating income came in at -52.45M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -52.45M |
| Pretax Income | -51.99M |
| Net Income | -51.99M |
| EBITDA | -52.23M |
| EBIT | -52.45M |
| Earnings Per Share (EPS) | -1.08 |
Achieve Life Sciences, Inc. holds 29.27M in cash and equivalents against 14.95M in total debt, resulting in a net debt position of -13.18M. Total book value stands at -270.27M, with working capital of 19.23M providing operational flexibility.
| Cash & Cash Equivalents | 29.27M |
| Total Debt | 14.95M |
| Net Debt | -13.18M |
| Equity (Book Value) | -270.27M |
| Book Value Per Share | -5.62 |
| Working Capital | 19.23M |
Achieve Life Sciences, Inc. produced -45.31M in operating cash flow over the past twelve months.
| Operating Cash Flow | -45.31M |
| Capital Expenditures | N/A |
| Free Cash Flow | -45.31M |
| FCF Per Share | -0.94 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -36.46 |
| FCF Yield | -32.05 |
Achieve Life Sciences, Inc.'s most recent stock split took place on July 31, 2020 with a 20:1 split ratio.
| Last Split Date | 7/31/2020 |
| Split Ratio | 20:1 |
Achieve Life Sciences, Inc. posts an Altman Z-Score of -13.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.06 |